Status:
UNKNOWN
Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta
Lead Sponsor:
rasha medhat abdul-hady
Conditions:
Placenta Accreta
Eligibility:
FEMALE
20-39 years
Brief Summary
The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.
Detailed Description
in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence ...
Eligibility Criteria
Inclusion
- pregnant women with history of scarred uterus
- plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S
- Gestational age from 28wks to full term
Exclusion
- pregnant women with fetus with congenital anomalies
- pregnant women with ovarian swelling
- pregnant women with medical disease
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04082507
Start Date
January 1 2017
End Date
August 30 2019
Last Update
September 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university maternity hospital
Cairo, Egypt